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~J~ lism was recognized in thelate 1800s,1 infant botu-
lism was not described until
1976.2,3 Adult-type botulism re-
sults from the ingestion of pre-
formed toxin in contaminated
food, while infant botulism ap-
pears to occur when spores are in-
gested, with in vivo germination
and elaboration of toxin.2 The ma-
jority of cases have been reported
in California, Utah, and Pennsylva-
nia.4,5 Many cases may go unrecog-
nized due to the often insidious
course and variable manifesta-
tions. These manifestations may
range from constipation and self-
limited weakness to respiratory fail-
ure and even sudden death. There
has been some controversy regard-
ing the association of the sudden
infant death syndrome (SIDS) and
Clostridium botulinum infection.
Two previous series identified C.
botulinum infection in 4.3%6 and
I5%7 of SIDS cases, respectively. A
recent prospective study, however,
failed to confirm the presence of C.
botulinum in 248 victims of SIDS,8
although this study utilized culture
alone, not toxin assay, for screening.
Pathogenesis
C. botulinum is a ubiquitous gram-
positive spore-forming organism. It
is found most commonly in soil
and agricultural products, al-
though honey has also been impli-
cated as a significant reservoir for
botulinum spores.9,10 C. botulinum
species are divided into four sub-
groups, all of which produce very
powerful neurotoxins. These neuro-
toxins are assigned letters A through
G. Infant botulism is caused primar-
ily by organisms producing toxins A
or B, although cases due to toxin
C,11 E, 12,13 F,14~15 and G7 have also
been reported. Infant botulism re-
sults from the ingestion of spores
with subsequent germination and
production of toxin, which is then
absorbed from the gut. 16 Animal
studies suggest that the cecum is
the primary site of multiplication
and toxin production,&dquo; while oth-
ers have demonstrated C. botu-
Linumin equal amounts through all
segments of the human colon.1s
Once released, toxin is absorbed
from the gut and binds specifically
and irreversibly to presynaptic




taining presynaptic vesicles.19,20 As
a result, neurotransmission is
blocked at all ganglionic and post-




One of the most significant risk
factors for the development of in-
fant botulism is age. The median
age of onset is approximately 2 to
4 months.21-23 Infant botulism has
been documented in adults, usu-
ally in the setting of disruption of
the normal function of the gastro-
intestinal tract, such as after sur-
gery, antibiotic therapy, or in the
presence of gastric achlorhydria.
This environment presumably per-
mits colonization in a manner simi-
lar to that observed in infants.9~°25
The ingestion of honey and, to a
lesser extent, of corn syrup has also
been identified as a risk factor for
the development of infant botu-
lism.22 Clearly, however, it is not the
only source of spores, since the ma-
jority of children who develop the
disease have not been exposed to
honey or corn syrup.
The significance of breast-feed-
ing as a risk factor remains some-
what controversial. It is clear that a
disproportionate number of in-
fants who are diagnosed with in-
fant botulism have been primarily
breast-fed. 23,26-28 When infants with
botulism who died suddenly were
compared with those who were
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FTable 1
SIGNS AND SYMPTOMS IN INfANTS WITH BOTULISM
NR = status of feature not reported
respiratory difficulty at presentatun
respiratory compromise at any time during courS3
hospitalized and who subsequently
recovered, however, the formula-
fed infants were overrepresented
in the sudden death group, while
more breast-fed infants were
among the hospitalized survivors
The intestinal flora differs signifi-
cantlv in breast-fed and non-breast-
fed infants. 29-33 The composition of
the intestinal microflora may play
a critical role in determining sus-
ceptibility to colonization and sub-
sequent germination of C. botulinum
spores. Dramatic changes in the in-
testinal flora occur during the tran-
sition from breast-feeding to
nonhuman food.33 It has been sug-
gested that the most susceptible pe-
riod for the development of infant
botulism may be during this transi-
tion period.34 In one large series, the
majority of cases were reported
within four weeks of the introduc-
tion of food other than breast milk
to infants who had previously been
exclusively breast fed.23
Outbreaks: Geography
While cases of infant botulism
have been reported throughout
the United States, the incidence is
significantly greater in certain re-
gions of the country. More than
half the cases reported in the U.S.
have come from California, Utah,
and Pennsylvania,4~5 states in which
levels of botulinal spores in the soil
are high.35 It also appears that
there are occasional outbreaks in
which the incidence of disease rises
significantly above its baseline in a
limited geographic area. Only six
cases of botulism have been re-
ported between 1977 and 1985 in
Colorado. Three of them were
from the same town of 800 people.
Two of the three infants shared a
crib, and all samples from their
environments yielded C. botulinum,
producing type A toxin.36 A cluster
of 12 cases occurring over two years
was reported in Utah .2’ A unique
situation exists in Pennsylvania,
where nearly all of the cases of infant
botulism come from counties imme-
diately surrounding Philadelphia,
but almost none come from the city
itself or from the western part of the
state.26 No explanation for this phe-
nomenon has been identified.
Clinical Features
The infant with botulism is typi-
cally afebrile and may present with
constipation, weakness, poor suck,
and a weak cr y.4,10,21,28 Constipation
may precede the onset of other
symptoms by several weeks. 10,37
There is no apparent sex predilec-
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Table 2 Il
__ ~~~~~° a COMPLICATIONS IN INFANTS WITH BOTULISM
SIADH = syndrome of inappropriate antidiuretic hormone production
NR = staturof feature not reported ’ - - j __
tion.21 Infants typically range from
6 weeks to 6 months of age at pres-
entation. One study of 57 infants
found an average age at diagnosis
of 102 days (range 18 to 219 days) .21
Autonomic nervous system in-
volvement generally occurs in-
itially, followed by motor deficits,
which often progress in a descend-
ing fashion, with early cranial nerve
involvement preceding trunk and
limb muscle weakness.34,37 Auto-
nomic impairment may cause dry
mucous membranes (which can be
misinterpreted as dehydration),
urinary retention, gastrointestinal
(GI) dysmotility, cardiac arrhyth-
mias, alternating skin flushing and
pallor, and blood pressure instabil-
ity. Cranial nerve palsies may be
manifested as impaired ocular mo-
tility, ptosis, mydriasis, loss of head
control, facial weakness, or an im-
paired gag reflex and suck. Infants
may experience pharyngeal pool-
ing of secretions or poor feeding.
If airway protective mechanisms
are sufficiently impaired, they may
be susceptible to aspiration. Pe-
ripheral neuromuscular involve-
ment may produce hypotonia as
well as diminished spontaneous
movements and reflexes. Dia-
phragmatic involvement may lead
to progressive respiratory failure.
The relative frequency of
symptoms reported in three pre-
vious series of patients is shown in
Table 1.~.28 The most common
symptoms include weakness, swal-
lowing difficulties with diminished
suck and poor feeding, constipa-
tion, weak cry, and diminished gag
reflexes. Although a relatively
small number of infants have respi-
ratory difficulty at presentation,’1 a
large number (77% to 89%) de-
velop respiratory failure and/or
impaired airway protective reflexes
and require intubation and me-
chanical ventilation during their
course. 21,23 The presence of weak-
ness suggests blockade of approxi-
mately 75% or more of the recep-
tors at the neuromuscular
junction,38 but diaphragmatic func-
tion may not be compromised until
90% to 95% of the receptors are
blocked .391’ Thus, respiratory fail-
ure may be a relatively late sign of
disease progression. Intubation is
often required for airway protec-
tion and to avoid the complications
of sudden respiratory compromise.
It is important to remain aware
of the variable severity and rates
of disease progression in infants
with botulism and to ensure close
cardiorespiratory monitoring. Mani-
festations may vary from benign
subclinical infection to fulminant
progression and death within
hours. The symptoms may wax and
wane significantly as gradual im-
provement occurs. The pattern of
resolution generally reverses the
sequence of the appearance of
symptoms. Symptoms often peak
by two or three weeks and begin to
resolve, although full resolution
may take up to several months.
Hospitalizations range from two to
201 days, with an average of ap-
proximately one to 1.5 months. 4,21
Table 2 compares the associated
complications in two previous se-
ries of patients.21,42 A majority of
the complications reflect the high
frequency of respiratory compro-
mise and mechanical ventilation of
these patients. Other complications
include syndrome of inappropriate
antidiuretic hormone production
(SIADH), particularly in mechani-
cally ventilated patients, and uri-
nary tract infections, presumably
secondary to urinary retention
with autonomic dysfunction. Sei-
zures may occur in a small number
of patients, although the mecha-
nism is not well understood. Ami-
noglycoside use may precipitate rapid
progression and respiratory failure
via potentiation of neuromuscular
blockade by the botulinum toxin.
672
Eight of 11 patients receiving ami-
noglycosides in one study experi-
enced rapid clinical deterioration.~’9
Differential Diagnosis
Several disorders may mimic in-
fant botulism and must be consid-
ered in the evaluation of the infant
presenting with poor feeding, leth-
argy, and diffuse progressive weak-
ness. These include sepsis,
meningitis/encephalitis, dehydra-
tion, electrolyte imbalance, myas-
thenia gravis, polio, Reye syndrome,
hypothyroidism, tick paralysis, Guil-
lain-Barr6 syndrome, heavy metal in-
gestion, carbon monoxide poisoning,
snakebite, cerebrovascular acci-
dents, and various metabolic disor-
ders. Not uncommonly, infants
with botulism are initially pre-
sumed to be septic or dehydrated
at presentation. Other diagnoses
may be entertained only after
symptoms fail to improve or pro-
gress despite rehydration and em-
piric broad-spectrum antibiotic
therapy. Misdiagnosis is common
and may have catastrophic conse-
quences if cardiorespiratoiy func-
tion is not monitored closely.
The characteristic presence of
constipation, often preceding the
onset of other symptoms, and the
absence of fever are useful his-
torical characteristics to help dif-
ferentiate botulism from other
infectious disorders. The descend-
ing progression of motor neurologic
signs in botulism contrasts with the
ascending progression with sensory
changes found in Guillain-Barré syn-
drome and other demyelinating
processes. Although clinical im-
provement with empiric neostig-
mine or edrophonium may suggest
myasthenia gravis, clinical im-
provement may also occur in other
disorders. Some researchers have re-
ported equivocal responses to edro-
phonium in infants with botulism.&dquo;
Diagnosis
Definitive diagnosis requires
the isolation of organism and/or
toxin from stool specimens. C. bot-
ulinum has been isolated from the
stool of affected infants as late as
158 days after the onset of symp-
toms, and toxin, up to 138 days.&dquo;
Stool specimens should be refrig-
erated after collection, but no spe-
cific preparation is required before
processing. Laboratory proce-
dures for the culture of C. botu-
linum, as well as toxin isolation and
identification, have been de-
scribed previously in detail. 44 Cul-
ture of the organism utilizes both
enrichment and selective media.
Briefly, this involves incubation of
specimen in chopped-meat-glu-
cose-starch medium for four days,
followed by selective culture on
egg yolk agar plates for two days.45
Toxin isolation and identification
is accomplished via mouse lethality
testing, with typing confirmed by
neutralization of toxin with spe-
cific antisera.44 Detection of toxin
can take anywhere from one to
four days, with specific typing
often taking an additional four
days.46 Testing is typically per-
formed at state health depart-
ments or the Centers for Disease
Control and Prevention.
Given the time often required to ~
obtain stool and isolate organism
and/or toxin, many investigators
have advocated clinical features
and electromyography (EMG) as
means of establishing a presump-
tive diagnosis, with stool studies
providing confirmation. The func-
tional denervation of the muscle,
which occurs as a result of im-
paired acetylcholine release at the
neuromuscular junction, gives rise
to abnormal spontaneous activity
at the motor end-plate and the
brief-duration, small-amplitude,
overly abundant motor unit poten-
tials (BSAPs) seen on EMG. Addi-
tionally, analogous to posttetanic
potentiation, a marked incre-
mental response to high-frequency
(20 to 50 Hz) repetitive stimulation
may be seen, as repetitive stimula-
tion enhances acetylcholine re-
lease by unaffected presynaptic
nerve terminals .47 Nerve conduc-
tion studies are normal .47 Al-
though not pathognomonic,
these findings in the appropriate
clinical setting may strongly sup-
port the diagnosis of botulism. A
recent retrospective review, how-
ever, found that four of 11 micro-
biologically confirmed cases of
infant botulism did not display the
characteristic EMG changes.48 It
appears, then, that normal elec-
trodiagnostic studies may not ex-
clude the presence of C. botulinum
infection. Clinical history and
physical exam findings consistent
with botulism should be evaluated
thoroughly and include EMG as
well as stool studies.
Treatment and Outcome
The cornerstone of manage-
ment of the infant with botulism is
meticulous supportive care. There
is no current evidence to support
the use of antibiotics or botulinum
antitoxin. A trial of human-derived
botulism immune globulin is
planned.49 The use of gentamicin
or tobramycin may potentiate
neuromuscular blockade39,so and is
thus contraindicated. Adequate
pulmonary toilet and monitoring
of cardiorespiratory function are
essential. Intubation may be re-
quired for airway protection or
respiratory failure. Tube feeding
may be necessary if swallowing
mechanisms are impaired, al-
though parenteral hyperalimenta-
tion may be required if significant
GI dysmotility is also present. As
noted previously, the duration of
hospitalization is approximately
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one to 1.5 months, on average. 4,21
A review of the experience at Chil-
dren’s Hospital of Philadelphia
found that three of 63 infants (5%)
with botulism experienced recur-
rence of symptoms after their in-
itial recovery and hospital
discharge.51 There were no identi-
fiable predictors of relapse. These
infants also ultimately returned to
normal function after relapse. Over-
all, the mortality rate of infants with
botulism has been estimated at less
than 5% in hospitalized patientS.4
With close monitoring and suppor-
tive care, gradual improvement and
return to baseline function may be
expected.
Conclusion
Infant botulism may present
with a variety of manifestations and
may be difficult to differentiate
from other disorders solely on
clinical grounds. It should be con-
sidered in the evaluation of infants
presenting with constipation, poor
feeding, and hypotonia. Definitive
diagnosis requires the isolation of
organism or its toxin from stool
specimens, although the presump-
tive diagnosis may be established
by the characteristic EMG pattern.
With meticulous supportive care
measures, virtually all infants may
be expected to have a gradual but
full recovery.
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